Table 1 Characteristics of included studies
Study | Sample size | Study design | Intervention | Control | Outcomes assessed | Outcomes measure | Length of follow-up | Knees available at final follow-up |
|---|---|---|---|---|---|---|---|---|
Joseph et al. [14] | 64 (32/32) | RCT | Avon (Stryker)/FPV (Wright Medical)/Zimmer (Zimmer Biomet) for PFA | NexGen (Zimmer Biomet)/Vanguard (Zimmer Biomet)/Triathlon (Stryker)/Medial Pivot (MicroPort orthopedics) for TKA | WOMAC, OKS, AKSS, UCLA, complications | WOMAC, OKS, AKSS, UCLA, complications | 60 months | 43 (20 TKA; 23 PFA) |
Odgaard et al. [15] | 100 (50/50) | RCT | Avon (Stryker) for PFA | PFC (DePuy) for TKA | OKS, KOOS, SF-36, complications | OKS, KOOS, SF-36, complications | 2 years | 93 (47 TKA; 46 PFA) |
Dahm et al. [16] | 45 (23/22) | Retrospective cohort study | Avon (Stryker) for PFA | Zimmer (Warsaw)/SIGMA (DePuy) for TKA | AKSS, UCLA, KSS, satisfaction, complications | AKSS, UCLA, KSS, satisfaction, complications | 29 months for PFA, 27 months for TKA | 45 (23 PFA; 22 TKA) |
Clement et al. [19] | 108 (54/54) | A retrospective case-matched cohort | Avon (Stryker) for PFA | Triathlon (Stryker) for TKA | OKS, SF-12, satisfaction, complications | OKS, SF-12, satisfaction, complications | 9.2 years | 87 (41 PFA; 46 TKA) |
Perrone et al. [17] | 34 (19/15) | Retrospective cohort study | PFJ (Zimmer) for PFA | The NexGen LPS (Zimmer Biomet) for TKA | OKS, KOOS, Kujala Score, complications | OKS, KOOS, Kujala Score, complications | More than 3 years | 34 (19 PFA; 15 TKA) |
Kamikovski et al. [18] | 46 (23/23) | A retrospective case-matched cohort | Avon (Stryker)/PFJ(Zimmer) for PFA | TKA | KOOS, WOMAC, UCLA | KOOS, WOMAC, UCLA | 5.2 years for PFA; 5.4 years for TKA | 46 (23 PFA; 23 TKA) |